At a glance
- Originator Kyowa Hakko
- Class Antiallergics; Antiplatelets; Benzazepines; Small molecules
- Mechanism of Action Thromboxane synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 28 May 2001 Discontinued-Preclinical for Thrombosis in Japan (Unknown route)
- 22 Sep 1998 No-Development-Reported for Thrombosis in Japan (Unknown route)
- 13 Nov 1995 New profile